Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)

National Institutes of HealthAmount not specifiedDue Jan 7, 2028

Researchers Schools & universities Narrow eligibility

Deadline: Jan 7, 2028
Posted: Nov 6, 2024
Award amount: Amount not specified
Focus areas: Education Health

Don’t miss this deadline

We’ll email you before Jan 7, 2028 so you have time to apply.

In plain English

This NIH (R01) opportunity funds collaborative research on chronic or delayed adverse effects of cancer therapies and mechanism-based interventions to prevent or reduce them. It is aimed at research and academic institutions, not individuals or typical nonprofits/small businesses. No specific award amount is stated.

AI-generated summary to help you decide quickly — verify the official eligibility rules before applying.

Who can apply

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

About this grant

The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to address adverse sequelae of cancer therapies that persist and become chronic comorbidities or develop as delayed posttreatment effects. This FOA supports basic, translational, and clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, or translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. Research projects should focus on mechanistic studies with translational endpoints and longitudinal clinical phenotyping to identify and validate clinical endpoints (biomarkers, imaging, patient-reported outcomes, or combined elements) for future use in clinical trials that will evaluate the efficacy of interventions designed to prevent or reduce specific adverse sequelae.

Let AI draft your application

Your first draft is free: a narrative and budget outline tailored to this grant, emailed to you. Drafts are written in a nightly batch, so it arrives by email later — not instantly on this page.

Application Kit — $49 one-time

Winner intelligence + a first-draft narrative grounded in applications that actually won. One payment, no subscription.

Get the Application Kit →

Related grants

Other open grants funding Education and Health — soonest deadline first.

Also listed under National Institutes of Health, Education Grants and Health Grants.

Source: public records via Grants.gov. UseGrants is an independent aggregator, not affiliated with any funding agency. Always confirm details on the official listing before applying.